Stockscreener 앱 받기
96.72
1.12%
-1.10
시간 외 거래:
96.72
Revvity Inc 주식(RVTY)의 최신 뉴스
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
How To Trade (RVTY) - news.stocktradersdaily.com
Are Revvity, Inc.'s (NYSE:RVTY) Mixed Financials Driving The Negative Sentiment? - simplywall.st
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows - SelectScience
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus By Investing.com - Investing.com Canada
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus - Investing.com
Transcript : Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Revvity To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET - Nasdaq
Wellington Management Group LLP Has $743,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com
Revvity gets FDA nod for its automated tuberculosis test - MSN
4 Mass. Rulings You May Have Missed In May - Law360
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Millennium Management LLC Trims Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers - Defense World
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen - Defense World
Zacks Research Forecasts Revvity’s Q1 Earnings (NYSE:RVTY) - Defense World
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Technology Networks
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Ameriprise Financial Inc. Increases Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Element Biosciences Welcomes Dr. Madhuri Hegde to its Board of Directors - Business Wire
Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.
Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo
Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India
Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
Med-tech financings and guidance strong despite tariffs - BioWorld MedTech
Revvity (NYSE:RVTY) Stock Rating Upgraded by UBS Group - Defense World
1.01%
0.96%
자본화:
|
볼륨(24시간):